Pimonidazole

Pimonidazole (CAS No.: 70132-50-2) is a bioreductive small-molecule hypoxia marker widely employed in oncology research to detect and characterize hypoxic regions within solid tumors. Under low-oxygen conditions, it undergoes enzymatic reduction of its nitro group, leading to the formation of reactive intermediates that covalently bind intracellular macromolecules, particularly proteins, thereby enabling selective accumulation in hypoxic cells. This mechanism supports its use as an immunochemical probe for both qualitative and quantitative assessment of tumor hypoxia, a critical microenvironmental factor associated with resistance to radiotherapy and chemotherapy. Pimonidazole is commonly utilized in conjunction with immunohistochemical and imaging techniques to map hypoxic gradients and to complement analyses of tumor cell proliferation and therapeutic response. Its favorable properties, including chemical stability, water solubility, and broad tissue distribution, have facilitated its application across in vitro cell-based assays and in vivo animal models, where it is typically administered in aqueous formulations. Although not primarily characterized by conventional potency metrics such as IC50 or EC50 due to its role as a biomarker rather than a direct cytotoxic agent, its activity is functionally evident in hypoxia-dependent labeling at concentrations generally spanning the micromolar range, with specific experimental conditions tailored to study design. This compound is extensively applied in cancer biology, drug development, and translational research to evaluate hypoxia-driven pathways and to support the development of hypoxia-targeted therapies.